This study is designed to determine the efficacy of high nicotine-specific antibody titers in smoking cessation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
200
Novartis Investigative Site
Mainz, Germany
Novartis Investigator Site
Neuss, Germany
Smoking status
Time frame: 12 weeks
Exhaled carbon monoxide
Time frame: 12 weeks
Smoking status at various time intervals from target quit date to the end of the study
Time frame: 52 weeks
Safety and tolerability
Time frame: 52 weeks
Immunogenicity (specific anti-nicotine antibodies in serum)
Time frame: 52 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.